AMRI Further Expands Discovery Capabilities in India
Srinivas Nanduri, Ph.D., was hired as Director of Medicinal Chemistry in India, reporting to Subramanyam Maddala, President of India Operations. In addition, Suneel Kumar Bommisetty, Ph.D., was hired as Senior Research Associate of Computational Chemistry, reporting to Dr. Nanduri. These newly created positions will further strengthen AMRI's capabilities in problem-solving medicinal chemistry and complement its current strength in custom synthesis at HRC.
In his most recent role as Research Director at Aurigene, Dr. Nanduri was responsible for the execution and overall supervision of multiple integrated drug discovery projects – from hit generation through lead optimization. Prior to that, he was a Chief Scientific Manager at Biocon-BMS Research Centre, where he led projects in the therapeutic areas of oncology, obesity and central nervous system disorders. Dr. Nanduri also had worked at Dr. Reddy's, where he led multiple medicinal chemistry projects in oncology and metabolic disorders, as well as a number of natural products projects in the area of anti-cancer therapy. Dr. Nanduri earned a Ph.D. in Organic Chemistry from Sri Sathya Sai Institute in Andhra Pradesh, India.
Dr. Bommisetty joins AMRI from GVK Biosciences Pvt. Ltd. and brings more than eight years of computational chemistry experience to HRC. He began his career as a Research Associate in 2004 while he obtained his Ph.D. in Computational Chemistry from JNTU. He played a dual role in GVK as a Scientific Associate and also as a senior faculty in GVK Bio campus, leading theory classes and lab sessions on Molecular Modeling, Homology Modeling, Structure-based Drug Design and Analogue-based Drug Design.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.